The 2nd European Myeloma Network (EMN) was held virtually, on March 3–6, 2021.

Experts in the field came together online to discuss and debate the latest updates in the field.

Explore all the latest in myeloma below!

View all videos

EMN 2021

European Myeloma Network (EMN)
March 3–6, 2021
VJHemOncVJHemOnc@VJHemOnc·
2h

First-in-human study of intratumoral injection of SYNB1891 in patients with refractory advanced solid tumors or #Lymphoma.

w/ @FilipJankuMD of @MDAndersonNews: http://ow.ly/IhFS50Et9bU

@AACR #AACR21 #HemOnc #Lymsm #CaxTx

Reply on Twitter 1384775177834205184Retweet on Twitter 1384775177834205184Like on Twitter 13847751778342051842Twitter 1384775177834205184
VJHemOncVJHemOnc@VJHemOnc·
16h

Changes in mast cell number & immunophenotype in patients with #Mastocytosis treated with avapritinib.

w/ Tracy George (@UofUMedicine): http://ow.ly/Nn1b50Et98d

@AACR #AACR21 #HemOnc #MPNsm #ImmunoOnc

Reply on Twitter 1384563809453498368Retweet on Twitter 1384563809453498368Like on Twitter 13845638094534983682Twitter 1384563809453498368
VJHemOncVJHemOnc@VJHemOnc·
22h

#iwCART21 begins tomorrow but there’s still time to apply for registration below ⬇️

Apply to register: http://ow.ly/Ugie50DW8HZ

@VJHemOnc #iwCART21 #CART #CARTcell #Immunotherapy #tcellrx #CellularTherapy #HemOnc #MMsm #Leusm #Lymsm #OncoAlert

Reply on Twitter 1384477487590219777Retweet on Twitter 13844774875902197771Like on Twitter 13844774875902197772Twitter 1384477487590219777
VJHemOncVJHemOnc@VJHemOnc·
20 Apr

myDRUG: investigating precision medicine approaches in patients with #MultipleMyeloma, w/ @AuclairDan from @theMMRF:

http://ow.ly/R97D50EsR5K

#ESHMM2021 @ESHaematology #HemOnc #MMsm #Myeloma #CaGenome #CTSM #TrialUpdate

Reply on Twitter 1384425332577607680Retweet on Twitter 13844253325776076801Like on Twitter 13844253325776076804Twitter 1384425332577607680
VJHemOncVJHemOnc@VJHemOnc·
20 Apr

#AACR21 has given us plenty to think about and we hope you’ve found it informative too! 💭

Check out 👉http://VJHemOnc.com👈 for interviews with #HemOnc experts! 👩‍⚕‍👨‍⚕‍

@VJHemOnc @AACR #Leukemia #Lymphoma #Myeloma #MPNsm #Myelofibrosis #CLLsm #AMLsm #ALLsm #ImmunoOnc

Reply on Twitter 1384416810225868803Retweet on Twitter 13844168102258688031Like on Twitter 13844168102258688032Twitter 1384416810225868803
Load More...

EMN 2021

European Myeloma Network (EMN)
March 3–6, 2021

The 2nd European Myeloma Network (EMN) was held virtually, on March 3–6, 2021.

Experts in the field came together online to discuss and debate the latest updates in the field.

Explore all the latest in myeloma below!

View all videos
VJHemOncVJHemOnc@VJHemOnc·
2h

First-in-human study of intratumoral injection of SYNB1891 in patients with refractory advanced solid tumors or #Lymphoma.

w/ @FilipJankuMD of @MDAndersonNews: http://ow.ly/IhFS50Et9bU

@AACR #AACR21 #HemOnc #Lymsm #CaxTx

Reply on Twitter 1384775177834205184Retweet on Twitter 1384775177834205184Like on Twitter 13847751778342051842Twitter 1384775177834205184
VJHemOncVJHemOnc@VJHemOnc·
16h

Changes in mast cell number & immunophenotype in patients with #Mastocytosis treated with avapritinib.

w/ Tracy George (@UofUMedicine): http://ow.ly/Nn1b50Et98d

@AACR #AACR21 #HemOnc #MPNsm #ImmunoOnc

Reply on Twitter 1384563809453498368Retweet on Twitter 1384563809453498368Like on Twitter 13845638094534983682Twitter 1384563809453498368
VJHemOncVJHemOnc@VJHemOnc·
22h

#iwCART21 begins tomorrow but there’s still time to apply for registration below ⬇️

Apply to register: http://ow.ly/Ugie50DW8HZ

@VJHemOnc #iwCART21 #CART #CARTcell #Immunotherapy #tcellrx #CellularTherapy #HemOnc #MMsm #Leusm #Lymsm #OncoAlert

Reply on Twitter 1384477487590219777Retweet on Twitter 13844774875902197771Like on Twitter 13844774875902197772Twitter 1384477487590219777
VJHemOncVJHemOnc@VJHemOnc·
20 Apr

myDRUG: investigating precision medicine approaches in patients with #MultipleMyeloma, w/ @AuclairDan from @theMMRF:

http://ow.ly/R97D50EsR5K

#ESHMM2021 @ESHaematology #HemOnc #MMsm #Myeloma #CaGenome #CTSM #TrialUpdate

Reply on Twitter 1384425332577607680Retweet on Twitter 13844253325776076801Like on Twitter 13844253325776076804Twitter 1384425332577607680
VJHemOncVJHemOnc@VJHemOnc·
20 Apr

#AACR21 has given us plenty to think about and we hope you’ve found it informative too! 💭

Check out 👉http://VJHemOnc.com👈 for interviews with #HemOnc experts! 👩‍⚕‍👨‍⚕‍

@VJHemOnc @AACR #Leukemia #Lymphoma #Myeloma #MPNsm #Myelofibrosis #CLLsm #AMLsm #ALLsm #ImmunoOnc

Reply on Twitter 1384416810225868803Retweet on Twitter 13844168102258688031Like on Twitter 13844168102258688032Twitter 1384416810225868803
Load More...

Latest Updates

View all
2:22
Treating young patients with myeloma
Michele Cavo • 6 Mar 2021
2:09
CARTITUDE-1: cilta-cel improves HRQoL for patients with myeloma
Thomas Martin • 9 Mar 2021
2:15
Unravelling drug resistance and sensitization
Michel Delforge • 10 Mar 2021
1:44
POLLUX & CASTOR analysis: MRD- with dara-combination regimens
Sagar Lonial • 11 Mar 2021

MRD

View all
2:09
DART4MM: daratumumab in myeloma patients with VGPR to first-line therapy
Alessandro Gozzetti • 24 Feb 2021
1:55
MRD monitoring for myeloma
Bruno Paiva • 24 Feb 2021

Real-World Data

View all
2:00
Real-world data: KRd in R/R multiple myeloma
Elena Zamagni • 2 Mar 2021
3:11
Long-term control of myeloma treated with MABs at second relapse
Uros Markovic • 26 Feb 2021

Immuno-Oncology

View all
1:23
ANCHOR: melflufen plus dexamethasone with bortezomib or daratumumab in myeloma
Enrique Ocio • 19 Feb 2021
2:08
Monoclonal antibody therapies for multiple myeloma
Mattia D'Agostino • 26 Feb 2021

Trial Updates

View all
3:03
Long-term follow-up of ibrutinib in Waldenström’s macroglobulinemia
Steven Treon • 3 Mar 2021
3:08
Frailty subgroup analysis of the MAIA trial
Gordon Cook • 2 Mar 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals